Testing olokizumab for progressive lung scarring diseases
Part of Lungs & breathing clinical trials.
This trial tests a drug called olokizumab to see if it can slow down worsening lung scarring (fibrosis) in people with certain types of progressive interstitial lung diseases. It's for patients whose lung function has declined despite current treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of lung scarring (pulmonary fibrosis) that is getting worse.
- You are 18 or older.
- Your lung function (FVC) is between 45% and 80% of normal, and your DLCO is at least 30% of normal.
- You have not taken certain medicines like rituximab (within the last year) or high-dose steroids recently.
- You are willing to avoid pregnancy during and for 3 months after the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a combination of two drugs, nintedanib and tocilizumab, can help people with systemic sclerosis (a condition that causes skin and organ hardening) who also have lung scarring (interstitial lung disease). The goal is to find a treatment that can slow down the disease.
This study tests whether a new drug called nerandomilast can slow down scarring in the lungs for people with certain types of fibrosing interstitial lung disease (a condition where lung tissue becomes thick and scarred). You may qualify if you have lung scarring that is getting worse and haven't tried this or similar drugs before.
This trial tests new treatments for people with scleroderma-related lung disease. You may be eligible if you have systemic sclerosis with lung scarring, your symptoms started within the last 7 years, and you have not had certain prior treatments or transplants.
This trial tests efzofitimod to see if it can improve or slow lung disease caused by systemic sclerosis (scleroderma), and to check safety and side effects. It focuses on people with relatively early disease and measurable lung involvement on lung scans.
This study tests whether starting an early anti-scarring medication can help people with stable lung fibrosis. It aims to see if the treatment slows down the disease and improves quality of life.
This study tests an experimental medicine called HSK44459 to see if it can slow down progressive pulmonary fibrosis (PPF), a condition that causes lung scarring and breathing difficulty. The goal is to learn if the medicine can help people keep more of their lung function compared to a placebo.
Hear when a new Lung Diseases, Interstitial trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.